1-[(3R)-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea

• ChemBase ID: 154653
• Molecular Formular: C24H24N4O
• Molecular Mass: 384.47356
• Monoisotopic Mass: 384.19501141
• SMILES: Cc1cccc(c1)NC(=O)N[C@H]1CN(c2ccccc2C(=N1)c1ccccc1)C
• Canonical SMILES: Cc1cccc(c1)NC(=O)N[C@H]1CN(C)c2c(C(=N1)c1ccccc1)cccc2
• InChI: InChI=1S/C24H24N4O/c1-17-9-8-12-19(15-17)25-24(29)27-22-16-28(2)21-14-7-6-13-20(21)23(26-22)18-10-4-3-5-11-18/h3-15,22H,16H2,1-2H3,(H2,25,27,29)/t22-/m0/s1
• InChIKey: LIVVMCBMGZZRRY-QFIPXVFZSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[(3R)-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
• IUPAC Traditional name: 1-[(3R)-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
• Synonyms: N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N′-(3-methylphenyl)-urea; L-365260

Database IDs

• CAS Number: 118101-09-0
• PubChem SID: 162248791
• PubChem CID: 71311927

CALCULATED PROPERTIES

• Log P: 5.3743167
• Molar Refractivity: 118.3511 cm^3
• Polarizability: 43.95266 Å^3
• Polar Surface Area: 56.73 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: false
• Acid pKa: 13.403941
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): 3.4030075
• LogD (pH = 7.4): 5.030254

PROPERTIES

Physical Property

• Solubility: DMSO: >20 mg/mL
• Apperance: solid

Safety Information

• Storage Condition: desiccated
• European Hazard Symbols: Nature polluting (N); Toxic (T)
• Risk Statements: 25-50/53
• Safety Statements: 45-60-61
• GHS Pictograms: GHS06; GHS09
• GHS Signal Word: Danger
• GHS Hazard statements: H301-H400
• GHS Precautionary statements: P273-P301 + P310
• Storage Temperature: -20°C

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C24H22N4O2

DETAILS

Sigma Aldrich - L4795

Biochem/physiol Actions
L-365260 is a CCK2 selective antagonist. Enhances amphetamine-induced stimulation of locomotor activity in rats (a model of drug abuse), inhibits thyroid carcinoma (TT)-cell proliferation (potential therapeutic implication for cancer treatment); bilateral injection into the medulla reverses both tactile allodynia and thermal hyperalgesia.